An endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors.
Three main kinds of ERAs exist:
- selective ETA receptor antagonists (sitaxentan, ambrisentan, atrasentan, BQ-123, sparsentan, zibotentan, avosentan, edonentan, aprocitentan, clazosentan), which affect endothelin A receptors.
- dual antagonists (bosentan, macitentan, tezosentan), which affect both endothelin A and B receptors.[1]
- selective ETB receptor antagonists (BQ-788 and A192621) which affect endothelin B receptors are used in research but have not yet reached the clinical trial stage.
Macitentan, ambrisentan and bosentan are mainly used for the treatment of pulmonary arterial hypertension, while atrasentan is an experimental anti-cancer drug.
YouTube Encyclopedic
-
1/5Views:2 09926 6813 6881 4411 191
-
BOSENTAN AND ITS EFFECT ON ENDOTHELIN
-
Pulmonary Hypertension Treatment Explained Clearly by MedCram.com
-
Bosentan - Endothelin blocker
-
Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
-
Endothelins and the Heart Part 1
Transcription
References
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 22 February 2024, at 07:34